Free tool
FAERS Monitor: Avopef
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220200 or its brand name (Avopef, Etoposide). Reports on generic versions are filed under their own applications.
Reports
73,447
Serious
71,494
97% of reports
Hospitalization
24,902
Death reported
17,829
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use8,393
- febrile neutropenia7,746
- neutropenia5,069
- drug ineffective4,759
- disease progression4,532
- thrombocytopenia4,140
- pyrexia3,405
- anaemia3,353
- sepsis2,998
- product use in unapproved indication2,973
- death2,838
- pancytopenia2,784
- pneumonia2,510
- nausea2,494
- mucosal inflammation2,345
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 792 |
| 2005 | 881 |
| 2006 | 745 |
| 2007 | 988 |
| 2008 | 1,084 |
| 2009 | 1,045 |
| 2010 | 1,167 |
| 2011 | 1,773 |
| 2012 | 1,995 |
| 2013 | 1,567 |
| 2014 | 1,702 |
| 2015 | 2,269 |
| 2016 | 2,601 |
| 2017 | 3,664 |
| 2018 | 4,656 |
| 2019 | 4,902 |
| 2020 | 5,842 |
| 2021 | 5,788 |
| 2022 | 6,631 |
| 2023 | 6,994 |
| 2024 | 6,507 |
| 2025 | 5,644 |
| 2026 | 4,206 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,980,712 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 7,746 | 37.7 | 36.9 | 245,361 |
| mucosal inflammationSignal | 2,345 | 28.1 | 26.9 | 55,790 |
| pancytopeniaSignal | 2,784 | 15.0 | 14.4 | 34,542 |
| disease progressionSignal | 4,532 | 11.4 | 11.0 | 41,424 |
| neutropeniaSignal | 5,069 | 11.1 | 10.8 | 44,890 |
| thrombocytopeniaSignal | 4,140 | 11.0 | 10.6 | 36,312 |
| sepsisSignal | 2,998 | 7.9 | 7.6 | 17,617 |
| anaemiaSignal | 3,353 | 5.1 | 4.9 | 10,974 |
| product use in unapproved indicationSignal | 2,973 | 3.5 | 3.3 | 5,209 |
| pyrexiaSignal | 3,405 | 2.8 | 2.7 | 4,073 |
| off label useSignal | 8,393 | 2.8 | 2.7 | 9,746 |
| pneumoniaSignal | 2,510 | 2.2 | 2.1 | 1,714 |
| drug ineffective | 4,759 | 1.0 | 1.0 | 6 |
| death | 2,838 | 0.9 | 0.9 | 10 |
| nausea | 2,494 | 0.9 | 0.9 | 27 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.